Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 21, 2026 06:28 ET | Source: Junshi Biosciences

Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma

Toripalimab's NDA was approved for the 1st-line treatment of HER2 expressing urothelial carcinoma by the NMPA